Net Income (Loss) Attributable to Parent in USD of REGENEREX PHARMA, INC. from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
REGENEREX PHARMA, INC. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2010 to Q3 2025.
  • REGENEREX PHARMA, INC. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$814K, a 53.7% decline year-over-year.
  • REGENEREX PHARMA, INC. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$3.2M, a 136% decline year-over-year.
  • REGENEREX PHARMA, INC. annual Net Income (Loss) Attributable to Parent for 2024 was -$2.53M, a 28.7% increase from 2023.
  • REGENEREX PHARMA, INC. annual Net Income (Loss) Attributable to Parent for 2023 was -$3.54M, a 2481% decline from 2022.
  • REGENEREX PHARMA, INC. annual Net Income (Loss) Attributable to Parent for 2022 was -$137K, a 29.8% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

REGENEREX PHARMA, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$3.2M -$814K -$284K -53.7% 01 Jul 2025 30 Sep 2025 10-Q 17 Nov 2025
Q2 2025 -$2.92M -$664K -$391K -143% 01 Apr 2025 30 Jun 2025 10-Q 17 Nov 2025
Q1 2025 -$2.53M -$1.41M -$1.12M -382% 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025
Q4 2024 -$1.41M -$315K -$50.6K -19.1% 01 Oct 2024 31 Dec 2024 10-Q 07 Feb 2025
Q3 2024 -$1.36M -$530K +$2.27M +81.1% 01 Jul 2024 30 Sep 2024 10-Q 17 Nov 2025
Q2 2024 -$3.63M -$273K -$87K -46.9% 01 Apr 2024 30 Jun 2024 10-Q 17 Nov 2025
Q1 2024 -$3.54M -$293K -$247K -533% 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 -$3.3M -$264K -$215K -434% 01 Oct 2023 31 Dec 2023 10-Q 07 Feb 2025
Q3 2023 -$3.08M -$2.8M -$2.78M -15096% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024
Q2 2023 -$300K -$186K -$162K -700% 01 Apr 2023 30 Jun 2023 10-Q 04 Nov 2024
Q1 2023 -$137K -$46.3K +$2.16K +4.46% 01 Jan 2023 31 Mar 2023 10-K 24 Jun 2024
Q4 2022 -$139K -$49.4K +$30K +37.8% 01 Oct 2022 31 Dec 2022 10-Q 05 Feb 2024
Q3 2022 -$170K -$18.4K +$15.3K +45.4% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 -$185K -$23.2K +$10.7K +31.7% 01 Apr 2022 30 Jun 2022 10-Q 08 Nov 2023
Q1 2022 -$196K -$48.4K +$236K +83% 01 Jan 2022 31 Mar 2022 10-K 09 Jun 2023
Q4 2021 -$432K -$79.4K -$45.8K -136% 01 Oct 2021 31 Dec 2021 10-Q 24 Jan 2023
Q3 2021 -$386K -$33.8K -$7.99K -31% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$378K -$34K -$24.1K -246% 01 Apr 2021 30 Jun 2021 10-Q 07 Nov 2022
Q1 2021 -$354K -$284K -$467K -256% 01 Jan 2021 31 Mar 2021 10-K 28 Jun 2022
Q4 2020 $114K -$33.7K -$13.1K -63.9% 01 Oct 2020 31 Dec 2020 10-Q/A 03 Feb 2022
Q3 2020 $127K -$25.8K -$7.3K -39.5% 01 Jul 2020 30 Sep 2020 10-Q 01 Nov 2021
Q2 2020 $134K -$9.82K +$22.5K +69.6% 01 Apr 2020 30 Jun 2020 10-Q 01 Nov 2021
Q1 2020 $112K $183K +$199K 01 Jan 2020 31 Mar 2020 10-K 23 Jun 2021
Q4 2019 -$87.7K -$20.6K +$33.2K +61.8% 01 Oct 2019 31 Dec 2019 10-Q 11 Feb 2021
Q3 2019 -$121K -$18.5K -$13.7K -284% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 -$107K -$32.3K -$13.7K -73.7% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020
Q1 2019 -$93.6K -$16.5K -$2.45K -17.5% 01 Jan 2019 31 Mar 2019 10-K/A 11 Aug 2020
Q4 2018 -$91.1K -$53.7K -$43.3K -415% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020
Q3 2018 -$47.8K -$4.81K +$3.32K +40.8% 01 Jul 2018 30 Sep 2018 10-Q 30 Oct 2019
Q2 2018 -$51.1K -$18.6K -$1.47K -8.6% 01 Apr 2018 30 Jun 2018 10-Q/A 29 Jul 2019
Q1 2018 -$49.7K -$14K -$5.87K -72.3% 01 Jan 2018 31 Mar 2018 10-K 24 Jun 2019
Q4 2017 -$43.8K -$10.4K -$8.23K -372% 01 Oct 2017 31 Dec 2017 10-Q 04 Feb 2019
Q3 2017 -$35.6K -$8.13K 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q2 2017 -$17.1K 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 -$8.13K -$8.11K 01 Jan 2017 31 Mar 2017 10-Q 07 Nov 2017
Q4 2016 -$2.21K 01 Oct 2016 31 Dec 2016 10-Q 08 Feb 2018
Q1 2016 -$21* 01 Jan 2016 31 Mar 2016 10-Q 07 Nov 2017
Q4 2014 $860K -$52.7K +$202K +79.3% 01 Sep 2014 30 Nov 2014 10-K 03 Mar 2015
Q3 2014 $658K -$59.1K +$189K +76.2% 01 Jun 2014 31 Aug 2014 10-Q 20 Oct 2014
Q2 2014 $469K $1.14M +$1.39M 01 Mar 2014 31 May 2014 10-Q 23 Jul 2014
Q1 2014 -$923K -$172K +$72.6K +29.7% 01 Dec 2013 28 Feb 2014 10-Q 11 Apr 2014
Q4 2013 -$995K -$255K +$527K +67.4% 01 Sep 2013 30 Nov 2013 10-K 03 Mar 2015
Q3 2013 -$1.52M -$248K -$234K -1622% 01 Jun 2013 31 Aug 2013 10-Q 20 Oct 2014
Q2 2013 -$1.29M -$248K -$240K -2941% 01 Mar 2013 31 May 2013 10-Q 23 Jul 2014
Q1 2013 -$1.05M -$244K -$389K -269% 01 Dec 2012 28 Feb 2013 10-Q 11 Apr 2014
Q4 2012 -$660K -$782K 01 Sep 2012 30 Nov 2012 10-K/A 28 Feb 2013
Q3 2012 -$14.4K 01 Jun 2012 31 Aug 2012 10-Q 02 Oct 2013
Q2 2012 -$8.16K -$10K -541% 01 Mar 2012 31 May 2012 10-Q 15 Jul 2013
Q1 2012 $144K +$135K +1496% 01 Dec 2011 29 Feb 2012 10-Q 12 Apr 2013
Q2 2011 $1.85K 01 Mar 2011 31 May 2011 10-Q 16 Jul 2012
Q1 2011 $9.05K 01 Dec 2010 28 Feb 2011 10-Q 16 Apr 2012

REGENEREX PHARMA, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$2.53M +$1.02M +28.7% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025
2023 -$3.54M -$3.41M -2481% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025
2022 -$137K +$58.3K +29.8% 01 Apr 2022 31 Mar 2023 10-K 24 Jun 2024
2021 -$196K +$158K +44.7% 01 Apr 2021 31 Mar 2022 10-K 09 Jun 2023
2020 -$354K -$465K -417% 01 Apr 2020 31 Mar 2021 10-K 28 Jun 2022
2019 $112K +$205K 01 Apr 2019 31 Mar 2020 10-K 23 Jun 2021
2018 -$93.6K -$43.9K -88.4% 01 Apr 2018 31 Mar 2019 10-K/A 11 Aug 2020
2017 -$49.7K -$47.1K -1830% 01 Apr 2017 31 Mar 2018 10-K 24 Jun 2019
2016 -$2.57K 01 Apr 2016 31 Mar 2017 10-K 21 Jun 2018
2014 $860K +$1.86M 01 Dec 2013 30 Nov 2014 10-K 03 Mar 2015
2013 -$995K -$336K -50.9% 01 Dec 2012 30 Nov 2013 10-K 03 Mar 2015
2012 -$660K -$448K -211% 01 Dec 2011 30 Nov 2012 10-K/A 28 Feb 2013
2011 -$212K -$185K -675% 01 Dec 2010 30 Nov 2011 10-K/A 28 Feb 2013
2010 -$27.4K 01 Dec 2009 30 Nov 2010 10-K 28 Feb 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.